Jyong BiotechMENS
Recorded
Jyong Biotech AGM 2026
Review the key takeaways and the transcript of this earnings call.
PeriodFY 2026Duration1 min
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Speaker
I think the MCS-2 product is unique in its mechanism of action. It will bring about help to many patients for benign prostatic hyperplasia, where currently there is no treatment that can serve their needs. I think that the safety profile is remarkable, and based on this alone, it will stand out as a unique product and very specialized in this space.
Speaker
Have become one of the first five companies to get a phase III clinical trial approved by FDA, by U.S. FDA, and could be one of the first five companies to have a botanical drug approved by the U.S.
Keep exploring